Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck said on Thursday it had discontinued its trial of a combination of its experimental drug and blockbuster therapy Keytruda for the treatment of a type of lung cancer, after an interim analysis showed the drug was unlikely to succeed.

Merck stops experimental lung cancer drug combo trial

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Update on Phase 3 KeyVibe-008 Trial Evaluating Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With ES-SCLC.

Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

Pfizer

Vertex Pharmaceuticals

Amid the stock market turmoil, wagering on the best biotech stocks could be a savvy move. The stock market has been tumultuous lately, which could spur a pivot toward defensive biotech stocks.

The 3 Best Biotech Stocks to Buy in August 2024

Medtronic

Merck is finding ways to avoid a fast-approaching patent cliff by continuing to do what it's done for a while. Medtronic is a diversified healthcare giant with several important long-term growth catalysts.

2 Dividend Stocks to Buy and Never Sell

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody drug conjugates to include Merck's MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager. The companies will jointly develop and commercialize MK-6070 worldwide, except in Japan where Merck w.

Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070

Goldman Sachs recently discussed with Joe Romanelli, President of Human Health International at Merck & Co Inc MRK, to review Gardasil's performance and future outlook in China.

Merck's Blockbuster Vaccine Gardasil Sales In China: Analyst Highlights Challenges and Opportunities

Disney

Microsoft

Merck fell as it cut its guidance and performance from its HPV drug disappointed. Microsoft delivered a solid earnings report, but it wasn't good enough for the market.

Is It Time to Buy July's Worst-Performing Dow Jones Stocks?

Teva Pharmaceutical

Sometimes the best way to jump into an industry like biotech is to follow the popular trades. Though that may go against the common advice of avoiding hype cycles and the fear of missing out, seeing which biotech stocks are experiencing the highest 24-hour trading volumes can be a quick way to learn which catalysts are driving investors to the industry.

What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.

Merck (NYSE: MRK) recently reported its Q2 results, with revenues and earnings exceeding our estimates. The company garnered $16.1 billion in revenue and adjusted earnings of $2.28 per share, compared to our estimates of $15.9 billion and $2.20, respectively.

Should You Pick Merck Stock At $115 After A Q2 Beat?

Merck KGaA is seeing a faster-than-expected improvement in its semiconductor materials business, the German pharma and technology company said on Thursday.

Merck reports earlier-than-expected improvement in semiconductor market

Merck & Co Inc MRK reported better-than-expected second-quarter earnings and sales results on Tuesday.

Merck Analysts Slash Their Forecasts After Q2 Results

The prime culprit for yesterday's 9.8% drop in Merck was what seemed to be a rather slight slip in Gardasil revenue – Merck's HPV vaccine – which came in about $20 million below consensus. At $113 – $115 per share, MRK is now trading at 14x and 12x 2024 and 2025 consensus estimates for expected growth this year that compares to '22 $7.48 in EPS. Pfizer reported a good quarter yesterday, with a 2% revenue beat and a 30% EPS for y-o-y growth of 2%, 9% operating income growth and -2% decline in EPS.

Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins

Major U.S. equities indexes were mixed for the second straight day as tech stocks lost ground ahead of key earnings reports and a decision on interest rates from the Federal Reserve.

S&P 500 Gains and Losses Today: Merck Stock Plunges on Guidance Cut

Merck & Co., Inc. (NYSE:MRK ) Q2 2024 Earnings Conference Call July 30, 2024 9:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and CEO Caroline Litchfield - CFO Dean Li - President of Merck Research Labs Conference Call Participants Chris Schott - JPMorgan Umer Raffat - Evercore Carter Gould - Barclays Tim Anderson - Wolfe Research Steve Scala - TD Cowen Mohit Bansal - Wells Fargo Luisa Hector - Berenberg Dana Graybosch - Leerink Akash Tewari - Jefferies Trung Huynh - UBS Louise Chen - Cantor Chris Shibutani - Goldman Sachs Terence Flynn - Morgan Stanley Evan Seigerman - BMO Capital Markets James Shin - Deutsche Bank Operator Thank you for standing by. Welcome to the Merck & Co. Q2 Sales and Earnings Conference Call [Operator Instructions].

Merck & Co., Inc. (MRK) Q2 2024 Earnings Call Transcript

Merck (MRK) posts better than expected second-quarter results, backed by strong demand for blockbuster cancer drug Keytruda. The stock falls in pre-market trading, likely due to the EPS guidance slash.

Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View

Shares of Merck & Co. (MRK) tumbled Tuesday after the pharmaceutical giant cut its full-year adjusted profit guidance.

Merck Stock Slides on Lowered Adjusted EPS Guidance

Merck & Co. Inc. NYSE: MRK delivered a solid earnings report before the market opened on July 30, 2024. However, the stock was down over 4% in early trading after the company cut its full-year earnings forecast.

Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity

While the top- and bottom-line numbers for Merck (MRK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metrics

Pharmaceutical giants Merck & Co Inc  (NYSE:MRK) and Pfizer Inc (NYSE:PFE) today reported second-quarter results.

Options Traders Blast 2 Pharma Socks After Earnings

Merck (MRK) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $2.16 per share. This compares to loss of $2.06 per share a year ago.

Merck (MRK) Q2 Earnings and Revenues Top Estimates

Merck reported better-than-expected earnings, but the pharmaceutical giant's outlook fell short of expectations.

Merck Posts Stronger-Than-Expected Results, But Outlook Falls Short

Merck & Co Inc's (NYSE:MRK, ETR:6MK) shares rose 1.4% in pre-market trading after reporting higher-than-expected second-quarter results, driven by strong sales of its top-selling cancer drug, Keytruda.  It prompted the group to raise its sales target for 2024, though its 2024 earnings line has been tweaked lower to reflect one-off acquisition charges.

Merck higher pre-market as Q2 sales beat forecasts

Shares of Merck & Co. MRK, +2.01% slipped 0.6% in premarket trading Tuesday, after the drug maker reported second-quarter profit and sales that beat expectations, amid strength in sales of cancer treatment Keytruda, while providing a mixed full-year outlook. The company swung to net income of $5.46 billion, or $2.14 a share, from a loss of $5.98 billion, or $2.35 a share, in the same period a year ago.

Merck beats profit and sales expectations amid Keytruda strength, but provides mixed full-year outlook

Merck & Co posted higher-than-expected second-quarter results on Tuesday on strong growth of its blockbuster cancer immunotherapy Keytruda, the world's best-selling prescription medicine.

Merck second quarter tops Street view on strong Keytruda sales

Merck reported second-quarter revenue and adjusted earnings that topped estimates as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a new cardiovascular drug.  The pharmaceutical giant also raised its full-year sales forecast to a range of $63.4 billion to $64.4 billion, however it lowered its adjusted profit guidance to between $7.94 and $8.04 per share.

News for Merck Stock (MRK)